Xanthinol

Summary

Xanthinol (CHEMBL1624126) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 311.34 Da · C13H21N5O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1624126
Name	Xanthinol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	9913
Molecular formula	C13H21N5O4
Molecular weight	311.34
InChIKey	DSFGXPJYDCSWTA-UHFFFAOYSA-N

SMILES: CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CN(C)CCO)O

IUPAC name: 7-[2-hydroxy-3-[2-hydroxyethyl(methyl)amino]propyl]-1,3-dimethylpurine-2,6-dione

Also known as: XANTINOL NICOTINATE

Parent form; salt/anhydrous children: CHEMBL1560089

Patent coverage: 199 distinct patent families (637 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).